Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | KDM6B | O15054 | 1/20 | 0.56 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.56 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.56 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.56 |
| ▸ | HCAR2 | Q8TDS4 | 12/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2276841 | 0.93 | POLB (0.59) | HDAC1KDM6BKDM4DKDM4CEGLN3 | |
| SCHEMBL22022903 | 0.88 | MEN1 (0.60) | HCAR2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL2271181 | 0.87 | GAA (0.60) | KDM6BKDM4DKDM4CKDM4EALDH1A1 | |
| SCHEMBL22022871 | 0.86 | ALOX15 (0.57) | HCAR2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL2275804 | 0.82 | HCAR2 (0.63) | HDAC1KDM6BKDM4DKDM4CEGLN3 | |
| SCHEMBL2270139 | 0.82 | HCAR2 (0.62) | HCAR2KDM4EALDH1A1TSHRHSD17B10 | |
| SCHEMBL2275482 | 0.80 | HCAR2 (0.71) | HDAC1KDM6BKDM4DKDM4CEGLN3 | |
| SCHEMBL1307810 | 0.80 | ALOX15 (0.73) | KDM6BKDM4DKDM4CEGLN3HCAR2 | |
| SCHEMBL10497116 | 0.79 | HCAR2 (0.78) | KDM6BKDM4DKDM4CEGLN3HCAR2 | |
| SCHEMBL4219661 | 0.79 | KDM4C (0.64) | KDM6BKDM4DKDM4CKDM4EFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101094829-B | novel anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO.,LTD. (JP) | 2012-02-08 | — | — | CN | disclosed |
| US-7999132-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| EP-1820795-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | MMP13, MMP26, MMP11 | HDAC1 71/4885KDM6B 729/4885KDM4D 884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.